Related Experiment Video
Updated: May 9, 2025
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
18.9K
Managing Coagulation Using the Sonoclot Analyzer in Patients With Disseminated Intravascular Coagulation.
1Peng Wan is a chief physician, Department of Critical Care Unit, First Clinical Medical College of Three Gorges University, Yichang, Hubei, China.
Summary
The Sonoclot analyzer improved 30-day survival rates for disseminated intravascular coagulation (DIC) patients. This tool also reduced anticoagulation and transfusion needs, especially in sepsis and heatstroke cases.
Area of Science:
- Critical Care Medicine
- Hematology
- Medical Diagnostics
Background:
- Disseminated intravascular coagulation (DIC) management lacks proven outcome-improving tools.
- Evidence supporting the Sonoclot analyzer's clinical utility in DIC is limited.
Purpose of the Study:
- To assess the effectiveness of a Sonoclot analyzer-based algorithm in enhancing short-term prognosis for DIC patients.
- To compare clinical outcomes between a Sonoclot-guided approach and conventional coagulation assays.
Main Methods:
- A prospective study involving 279 patients with overt DIC, divided into conventional coagulation assay (CCA) and Sonoclot groups.
- Data on anticoagulation, transfusions, and 30-day survival were collected and analyzed post-algorithm implementation.
- Comparison of survival rates and resource utilization between the two groups.
Main Results:
- The Sonoclot group demonstrated a significantly higher 30-day survival rate (78.45%) compared to the CCA group (63.64%; P = .02).
- Heparin dosage, anticoagulation duration, and major bleeding rates were significantly lower in the Sonoclot group (P < .001).
- Transfusion requirements (fresh frozen plasma, platelets, cryoprecipitate) were substantially reduced in the Sonoclot group (P ≤ .03).
Conclusions:
- The Sonoclot analyzer shows potential as a valuable tool for guiding coagulation management in DIC.
- A Sonoclot-based algorithm may improve clinical outcomes, particularly for DIC patients with moderately severe sepsis or heatstroke.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
536
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
536
01:09Coagulation
3.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
3.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
3.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
3.6K
01:24Disorders of Hemostasis
638
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
638
01:16Clot Retraction and Fibrinolysis
2.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.4K
01:05Introduction to Hemostasis
3.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
3.9K